Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 19, 2024 5:57pm
84 Views
Post# 35941717

RE:RE:RE:RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

RE:RE:RE:RE:RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs March 06, 2024 - Ropes & Gray insight alert on the Biosecure Act.

Senate Committee Votes to Send the BIOSECURE Act to the Senate Floor

March 6, 2024

https://www.ropesgray.com/en/insights/alerts/2024/03/senate-committee-votes-to-send-the-biosecure-act-to-the-senate-floor

Plus:


New Executive Order Would Restrict Transfer of Certain Bulk Sensitive Personal Data and United States Government-Related Data to China and Other Countries of Concern 
February 29, 2024


On February 28, 2024, President Biden announced an Executive Order (“EO”) directing the Department of Justice (“DOJ”) to promulgate regulations that restrict or prohibit transactions involving certain bulk sensitive personal data or United States Government-related data and countries of concern or covered persons. The DOJ’s initially identified countries are China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela, and the restrictions would also apply to any entity owned by, controlled by, or subject to the jurisdiction or direction of a country of concern as well as any person “knowingly causing or directing, directly or indirectly, a violation” of the regulations.

As directed by the EO, on February 28, the DOJ published an Advance Notice of Proposed Rulemaking (“ANPRM”) on topics related to the implementation of the EO soliciting comments up to 45 days after the ANPRM is published in the Federal Register (typically posted a few days after the announcement), which would make comments due around April 15, 2024. The EO directs the DOJ to publish a proposed rule within 180 days of the EO publication, so on or before August 26, 2024.

https://www.ropesgray.com/en/insights/alerts/2024/03/new-executive-order-would-restrict-transfer-of-certain-bulk-sensitive-personal-data

<< Previous
Bullboard Posts
Next >>